Objective: Early severe graft dysfunction, as manifested by hypoxia and pulmonary hypertension, occurs in 10% to 20% of lung transplant recipients. We retrospectively investigated whether inhaled nitric oxide would reduce human lung allograft dysfunction by comparing postoperative hemodynamic data, gas exchange, and outcome in lung transplant recipients with early graft dysfunction treated with or without nitric oxide. Method: Among 243 adult lung transplant procedures, there were 32 patients (13.2%) in whom immediate severe allograft dysfunction developed (arterial oxygen tension/inspired oxygen concentration ratio < 150). Group 1 (n = 17) included patients who underwent transplantation before nitric oxide became available in our center and were treated conventionally. Group 2 (n = 15) included those treated with nitric oxide as soon as severe allograft dysfunction was diagnosed. Duration of nitric oxide therapy (20 to 60 ppm) was 15 to 217 hours (average 84 hours). Results:
D
espite improved preservation methods and perioperative management, severe allograft dysfunction occurs in 10% to 20% of lung transplant recipients.i, 2 Its associated severe hypoxia, pulmonary hypertension, and lung edema complicate postoperative management. Nitric oxide was reported to be an important endothelium-derived relaxing factor in 1987. 3 Rossaint and colleagues 4 reported in 1993 that extended treatment with inhaled nitric oxide for patients with severe adult respiratory distress syndrome reduces the pulmonary artery pressure without producing systemic vasodilatation and increases arterial oxygenation by improving ventilation-perfusion matching. We 5 recently tested the effect of short periods of nitric oxide inhalation on hemodynamics and arterial oxygenation in patients after bilateral lung transplantation. Nitric oxide dramatically improved the arterial oxygen tension/inspired oxygen fraction (Pao2/Fio2) ratio and lowered the mean pulmonary artery pressure in patients with impaired oxygenation. We 6 recently demonstrated that nitric oxide markedly improved posttransplantation gas exchange in canine lung allografts stored for 18 hours. The purpose of this report was to compare the effects of inhaled nitric oxide with conventional therapy in a group of lung transplant recipients with severe allograft dysfunction.
Patients and methods
Between September 1988 and December 1994, 243 consecutive single (n = 111) and bilateral sequential single (n = 132) lung transplants were performed at Barnes Hospital. En bloc double lung transplants (n = 8) performed in our early experience were not included in this study. Thirty-two patients (13.2%) had immediate severe allograft dysfunction, as manifested by a Pao2/Fio2 ratio less than 150. These 32 patients were divided into two groups. Group 1 (n = 17) included patients having lung transplantation before January 1993 (when inhaled nitric oxide became available in our institution) and treated conventionally. Group 2 (n = 15) included those patients having lung transplantation after February 1993 and treated with inhaled nitric oxide as soon as severe allograft dysfunction was diagnosed. These two groups were compared in regard to requirement for extracorporeal membrane oxygenation (ECMO), days requiring mechanical ventilation, airway complications, and mortality. In group 2, the effect of inhaled nitric oxide was evaluated by the changes of systemic and pulmonary hemodynamics and arterial blood gases measured before and during nitric oxide treatment.
Donor lungs were harvested by the technique we 7 have previously described. All donors were pretreated with systemic heparin and the pulmonary artery bed was flushed with modified Euro-Collins solution after prostaglandin E 1 (500/xg) administration. All transplant operations were performed by means of previously described techniques. ~ Cardiopulmonary bypass was used in all patients with pulmonary hypertension and in other patients as dictated by inadequate gas exchange or hemodynamics during transplantation. 9 Routine clinical monitoring of the patients included a radial arterial line and a 7.5F Swan-Ganz catheter (Baxter Healthcare Corp., Irvine, Calif.) positioned into the pulmonary artery through the internal jugular vein. Systemic, pulmonary artery, pulmonary wedge, and central venous pressures were recorded. Cardiac output was determined by the thermodilution method.
Postoperative sedation included intravenous fentanyl citrate and midazolam. Vecuronium bromide was given when indicated. Inotropic support, vasodilators, and diuretics were used as necessary to maximize hemodynamic stability and graft function. Prostaglandin E 1 (0.01 to 0.03 /zg/kg per minute) was administered routinely from 1989 unless significant hypotension was encountered. All patients received mechanical ventilation in the volumecontrolled mode with the application of positive endexpiratory pressure (5 to 15 cm H20 ). Ventilator settings were adjusted to provide adequate oxygenation as measured by Pao 2 and adequate ventilation as measured by arterial pH and carbon dioxide tension. Standard immunosuppression consisted of cyclosporine, azathioprine, steroid, and antilymphocyte antibody as reported previously. 1°
Nitric oxide was supplied from Scott Specialty Gases (Plumsteadville, Pa.) in cylinders containing nitric oxide in nitrogen in a concentration of 2200 ppm. The delivery system consisted of a reducing valve and a flowmeter. The nitric oxide gas mixture (1/8 to 1/4 L/min) was delivered into the inspiratory port of the ventilator. The concentration of nitric oxide was continuously measured from a sampling line at the Y connector attached to the endotracheal tube; a chemiluminescence device (model 42A, Thermoenvironmental Instruments, Franklin, Mass.) that was calibrated before each use with a calibration gas of known 25 _+ 1 ppm nitric oxide in nitrogen (Scott Specialty Gases) was used to obtain these measurements. The flow was adjusted according to the concentration measured by the analyzer. The starting dose of inhaled nitric oxide was 40 to 60 ppm and the gas was gradually weaned to 20 ppm. It was continued until its cessation did not cause deterioration in oxygenation or pulmonary artery pressure. Methemoglobin levels were measured every 2 to 6 hours with a Co-Oximeter (model 2500, Ciba-Corning, Medfield, Mass.) by means of a multiple wave-length spectrophotometric method. When methemoglobinemia (>6%) was noticed, 1 gm of ascorbic acid was given intravenously and the dose of nitric oxide was reduced. Informed consent was obtained from all patients for nitric oxide administration and the protocol for nitric oxide use was approved by the Human Studies Committee of Washington University.
All data are presented as the mean --the standard error of the mean. Significance was sought between the two groups with use of a )(2 test for nonparametric data and Student's t test for parametric data. Repeated-measures analysis of variance was used to test the effect of nitric oxide on systemic and pulmonary hemodynamics and also on arterial blood gas analysis. Statistical significance was determined at a p value of 0.05. (Table I) . Recipient age, recipient sex, donor age, donor Pao2, procedure, total ischemic time, use of cardiopulmonary bypass during transplant procedures, and initial Pao 2 (Fio 2 = 1.0) after reperfusion were not significantly different between the two groups.
Results

Demographic results
Comparison of outcome between the two groups. (Table II) . Three patients in each group required ECMO. Five of them, all three patients in group 1 and two patients in group 2, required ECMO immediately after transplantation because they could not be weaned from cardiopulmonary bypass owing to severe allograft dysfunction. In one group 2 patient ECMO was begun 24 hours after transplantation because of progressive allograft dysfunction despite nitric oxide treatment. Two patients requiring ECMO in each group ultimately recovered and one patient requiring ECMO in each group died of severe allograft dysfunction.
Duration of mechanical ventilation required was 17 2 5 days in group 1 and 12 2 3 days in group 2.
Four patients in group 1 had airway complications. Early fatal bronchial dehiscence occurred in two patients, one of whom underwent retransplantation without success, and late bronchial stenosis occurred in two patients. In contrast, no airway complication was encountered in group 2.
Hospital mortality was four of 17 (24%) in group 1 and one of 15 (7%) in group 2. Causes of death in group 1 were airway dehiscence in two patients, severe allograft dysfunction in one, and sepsis in one patient. One patient in group 2 died of severe allograft dysfunction.
Requirement of ECMO, duration of mechanical ventilation, airway complication, and hospital mortality did not reach statistical significance between the two groups.
Effect of inhaled nitric oxide. Nitric oxide treatment was initiated in the operating room in four patients and on arrival at the intensive care unit in five patients. In the remaining six patients, nitric oxide was initiated 1 to 10 hours after they arrived in the intensive care unit because of progressive allograft dysfunction. Duration of nitric oxide therapy was 15 to 217 hours (average 84 hours). The effect of nitric oxide on hemodynamics and arterial blood gases was evaluated by comparing the data obtained during nitric oxide therapy and those obtained immediately before nitric oxide therapy was initiated (baseline value). Data were obtained from 13 patients treated with inhaled nitric oxide, excluding two patients who required ECMO immediately after transplantation. Because the duration of nitric oxide therapy was different in each case, statistical analysis was performed on the data obtained during the first 8 hours (Table III) . Nitric oxide administration resulted in rapid improvement of arterial oxygenation and pulmonary artery pressure without affecting systemic pressure or cardiac index and caused a sustained improvement in these parameters during extended therapy ( Figs. 1 and 2) .
Transient methemoglobinemia (>6%) developed in two patients, 10.5% after 24 hours and 6.7% after 8 hours, respectively, on a nitric oxide concentration of 40 ppm. Both patients were successfully treated with ascorbic acid administration and reduction of nitric oxide dose. No complications were associated with nitric oxide administration.
Discussion
Early severe allograft dysfunction, as manifested by allograft edema, pulmonary hypertension, and decreased arterial oxygenation, develops in 10% to 20% of lung transplant recipients. I' 2 This dysfunction has been known as pulmonary reimplantation response. 11 Ischemia-reperfusion injury is thought to be the major cause of this phenomena. I2 A Endothelial dysfunction may play a central role in pulmonary hypertension. Acetylcholine relaxes preconstricted vascular smooth muscle by binding to muscarinic receptors on the endothelial cell, causing the release of a potent vasodilating substance called endothelium-derived relaxing factor. 16 In 1987, nitric oxide was reported to be an important endothelium-derived relaxing factor. 3 Nitric oxide is thought to diffuse from the endothelium to adjacent smooth muscle and produce relaxation through a cyclic guanosine monophosphate-dependent pathway. The vascular response to acetylcholine is altered in a number of conditions, such as chronic obstructive lung disease, 17 pulmonary hypertension after cardiopulmonary bypass, Is and lung transplantation 19'2° wherein significant endothelial nitric oxide production is inadequate. However, vasodilatation may be elicited by inhaled nitric oxide, an endotheliumindependent smooth muscle relaxant.
We previously tested the effects of short periods of nitric oxide inhalation (40 to 60 ppm) and systemic prostaglandin E 1 (0.03 to 0.06 mg/kg per minute) on hemodynamics and arterial oxygenation in patients after bilateral lung transplantation. 5 In patients with impaired oxygenation, nitric oxide improved PaoJFio2 ratio and lowered mean pulmonary artery pressure without systemic circulatory effects. In contrast, prostaglandin E 1 did not improve oxygenation and lowered systemic arterial pressure. Interestingly, in patients without impaired oxygenation, nitric oxide was of no benefit and paradoxically worsened oxygenation. We have also demonstrated the beneficial effects of inhaled nitric oxide on allograft dysfunction owing to reperfusion injury in a canine single lung transplant model. 6 On the basis of this experience and several reports on nitric oxide treatment for pulmonary hypertension [21] [22] [23] and adult respiratory distress syndrome, 4 extended inhaled nitric oxide treatment has been given to the 15 lung transplant recipients with severe allograft dysfunction since February 1993. Inhaled nitric oxide rapidly improved oxygenation and decreased pulmonary artery pressure without systemic circulatory effects. It should also be noted that inhaled nitric oxide does not cause tachyphylaxis. Because nitric oxide, an endothelium-independent smooth muscle relaxant, is delivered via the airway, pulmonary blood flow is redistributed away from nonventilated regions of the lungs and toward ventilated regions, thereby improving the matching of ventilation and perfusion. Another beneficial effect may be derived from a potential antineutrophil effect of nitric oxide. Our previous canine study demonstrated that preserved lung allografts treated with inhaled nitric oxide had decreased myeloperoxidase activity, indicating decreased neutrophil sequestration in comparison with that of untreated allografts.
Patients with severe lung allograft dysfunction usually require prolonged mechanical ventilation. We 24 have recently reported that prolonged mechanical ventilation is associated with an increased incidence of airway complications. Whether this increase is due to mechanical ventilation itself or to the parenchymal injury necessitating mechanical ventilation is not known. Our observations suggest that inhaled nitric oxide may shorten the time required for mechanical ventilation in patients with severe allograft dysfunction. Interestingly, four patients treated without nitric oxide had airway complications, two of which proved fatal. In contrast, no airway complications were noted when nitric oxide was used.
ECMO has been used when conventional measures for treatment of severe allograft dysfunction proved unsuccessfulY In our entire experience of 243 patients undergoing lung transplantation, only six patients required ECMO. Four of them survived and were discharged from the hospital. We have avoided the use of ECMO as much as possible because of the potential complications of bleeding, infection, and renal insufficiency. We speculate that at least two more patients would have required ECMO had nitric oxide not been available. On the other hand, one patient required ECMO 24 hours after transplantation because of progressive allograft dysfunction despite nitric oxide therapy. This patient's lung never recovered. Our current strategy is to use nitric oxide as the first therapeutic intervention in the presence of severe allograft dysfunction and to reserve ECMO for subsequent treatment failures or for circumstances in which euvolemic hemodynamic instability proves refractory to management with standard pressor and inotropic agents.
The absence of systemic vasodilatation with inhaled nitric oxide was confirmed in this study. The lack of systemic effects results from the rapid inactivation of nitric oxide by hemoglobin in red blood cells. 18 The reaction of hemoglobin and nitric oxide forms nitrosyl hemoglobin and subsequently methemoglobin. 26 Intravenously infused vasodilators such as prostaglandin El, on the other hand, cause both pulmonary and systemic vasodilatation. 5'15 The dose of a vasodilator agent is limited by concomitant dilatation of the systemic vasculature, leading to systemic arterial hypotension.
The therapeutic importance of our data on inhaled nitric oxide is evident but must be considered in conjunction with possible toxic effects. Nitric oxide can be converted by oxidation to nitric dioxide and other toxic agents such as peroxynitrite, resulting in lung injury. 27 Formation of methemoglobin may decrease oxygen delivery. There is indirect evidence that nitric oxide may be directly related to allograft rejection. In a rat left lung allograft model we 28 have recently demonstrated that inhibition of nitric oxide synthase by aminoguanidine markedly delayed the onset and decreased the severity of lung allograft rejection. Little evidence for nitric oxide toxicity exists with exposures less than 100 ppm in normal rats 27 and rabbits. 29 In fact, in our experience we observe no complications associated with extended nitric oxide inhalation for up to 217 hours. Transient mild methemoglobinemia occurred in two patients and was successfully treated with ascorbic acid administration. We did not encounter any episodes of intractable acute rejection.
In summary, this study demonstrates that inhaled nitric oxide improves gas exchange and decreases pulmonary artery pressure in patients with early allograft dysfunction. It also suggests that inhaled nitric oxide may shorten postoperative mechanical ventilation time, reduce airway complications, and reduce mortality in patients with severe lung allograft dysfunction.
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